603087 Stock Overview
A biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 1/6 |
Gan & Lee Pharmaceuticals. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥48.52 |
52 Week High | CN¥62.90 |
52 Week Low | CN¥32.10 |
Beta | 1.61 |
1 Month Change | -3.04% |
3 Month Change | 12.11% |
1 Year Change | 26.39% |
3 Year Change | -61.71% |
5 Year Change | n/a |
Change since IPO | -25.50% |
Recent News & Updates
Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates
Apr 29Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S
Mar 01Shareholder Returns
603087 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 4.5% | -0.1% | -0.4% |
1Y | 26.4% | -19.9% | -12.6% |
Return vs Industry: 603087 exceeded the CN Biotechs industry which returned -19.9% over the past year.
Return vs Market: 603087 exceeded the CN Market which returned -12.6% over the past year.
Price Volatility
603087 volatility | |
---|---|
603087 Average Weekly Movement | 5.9% |
Biotechs Industry Average Movement | 6.1% |
Market Average Movement | 6.6% |
10% most volatile stocks in CN Market | 10.0% |
10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 603087 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603087's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 4,482 | Kai Du | www.ganlee.com |
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices.
Gan & Lee Pharmaceuticals. Fundamentals Summary
603087 fundamental statistics | |
---|---|
Market cap | CN¥28.97b |
Earnings (TTM) | CN¥386.85m |
Revenue (TTM) | CN¥2.61b |
74.9x
P/E Ratio11.1x
P/S RatioIs 603087 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603087 income statement (TTM) | |
---|---|
Revenue | CN¥2.61b |
Cost of Revenue | CN¥726.12m |
Gross Profit | CN¥1.88b |
Other Expenses | CN¥1.50b |
Earnings | CN¥386.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.65 |
Gross Margin | 72.18% |
Net Profit Margin | 14.82% |
Debt/Equity Ratio | 0% |
How did 603087 perform over the long term?
See historical performance and comparison